Scarica l'app Stockscreener
27.53
0.11%
0.03
Dopo l'orario di chiusura:
27.53
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Rigel Pharmaceuticals Borsa (RIGL) Ultime notizie
RIGL PE Ratio & Valuation, Is RIGL Overvalued - Intellectia AI
Rigel Pharmaceuticals (RIGL) seeks approval for equity plan share increases at 2026 meeting - Stock Titan
How (RIGL) Movements Inform Risk Allocation Models - Stock Traders Daily
Rigel Pharmaceuticals Balances Breakout Growth With Caution - The Globe and Mail
Why Rigel Pharmaceuticals Shares Tanked - Yahoo
Hennion & Walsh Asset Management Inc. Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Jim Cramer blesses Rigel Pharmaceuticals as a spec as “it’s doing better than people realize” - MSN
Rigel Pharmaceuticals, Inc. (RIGL) stock price, news, quote and history - Yahoo Finance Singapore
Rigel Pharmaceuticals, Inc. (RIGL) Stock Price, News, Quote & History - Yahoo! Finance Canada
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
RIGL Stock Price, Quote & Chart | RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) - ChartMill
Rigel Pharmaceuticals’ pralsetinib shows efficacy in NSCLC clinical trial - TipRanks
Rigel Pharmaceuticals (RIGL) Reports Promising Results from ARRO - GuruFocus
Rigel announces publication of final ARROW clinical trial data on Gavreto® (pralsetinib) - MarketScreener
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology - PR Newswire
Why Rigel Pharmaceuticals Lost Big in December - AOL.com
Rigel Pharmaceuticals Receives 'Moderate Buy' Rating from Analysts - National Today
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Market Review: What is the Moat Score of Rigel Pharmaceuticals Inc2026 Highlights & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Jim Cramer Blesses Rigel Pharmaceuticals as a Spec as “It’s Doing Better Than People Realize” - Insider Monkey
Vanguard realignment leads to 0 shares reported for Rigel (RIGL) - Stock Titan
Jim Cramer Broke Down 16 Stocks Including Pharma Plays for Rising Oil - Insider Monkey
Rigel Pharmaceuticals (RIGL) Q4 earnings miss estimates - MSN
Rigel Pharmaceuticals Q4 2025 earnings preview - MSN
Rigel’s New Olutasidenib Interaction Study Signals Long-Game Strategy for RIGL Investors - TipRanks
Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure - Fierce Biotech
Rigel Pharmaceuticals shows rising relative strength; still shy of key benchmark - MSN
Rigel Pharmaceuticals (RIGL) Just Flashed Golden Cross Signal: Do You Buy? - MSN
Rigel enrols first subject in R289 Phase Ib expansion for MDS - MSN
Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update - Quantisnow
Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential? - MSN
Rigel Pharmaceuticals jumps on 2025 revenue guidance boost, Q3 beats - msn.com
RIGL stock rises 59% in a year: Time to buy, hold or sell? - MSN
Rigel Pharmaceuticals: Growing Where It Matters (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals (RIGL) earnings expected to grow: Should you buy? - MSN
Assessing Rigel Pharmaceuticals (RIGL) Valuation After Strong Q4 And Full Year 2025 Earnings Results - Sahm
Analysts Set Expectations for RIGL Q3 Earnings - MarketBeat
Surging Earnings Estimates Signal Upside for Rigel (RIGL) Stock - MSN
Rigel Pharmaceuticals (RIGL) EPS Spike On Non Cash Gains Challenges Bullish Narratives - Sahm
Rigel Pharmaceuticals’ Fast Track Ambitions Face Significant FDA Uncertainty - The Globe and Mail
Brokers Offer Predictions for RIGL Q1 Earnings - MarketBeat
This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges - AOL.com
Rigel Pharmaceuticals (RIGL) Projects Revenue Decline for 2026 - GuruFocus
Rigel Pharma stock slides on 2026 outlook (RIGL:NASDAQ) - Seeking Alpha
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap DownWhat's Next? - MarketBeat
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Citi Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $71 - 富途牛牛
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):